Latest Breaking News On - Tranquis therapeutics - Page 1 : comparemela.com

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M D , Ph D as Chief Medical Officer

BETHESDA, Md., April 01, 2024 Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation allosteric small molecule therapies,.

Elio ambrosioNic johnsonJonas hannestadBristol myers squibbMatthias alderGain therapeutics incNeuropsychiatric instituteExchange commission onCompany annual report on formDuke school of medicineClinical development at alkahestUniversity of oviedoEuropean union horizonMichaelj fox foundation for parkinson researchCompensation committee of gain board directorsSilverstein foundation for parkinson

Gain Therapeutics (GANX) Appoints Jonas Hannestad as Chief Medical Officer

Gain Therapeutics (GANX) Appoints Jonas Hannestad as Chief Medical Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jonas hannestadBristol myers squibbMatthias alderGain therapeutics incNeuropsychiatric instituteCompensation committee of gain board directorsDuke school of medicineUniversity of messinaUniversity of oviedoYale school of medicineClinical development at alkahestClinical neuroscience research unitGain therapeuticsChief medical officerTranquis therapeuticsCapacity bio

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M D , Ph D as

BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation

Nic johnsonBristol myers squibbElio ambrosioJonas hannestadMatthias alderUniversity of messinaSilverstein foundation for parkinsonMichaelj fox foundation for parkinson researchClinical neuroscience research unitYale school of medicineCompensation committee of gain board directorsExchange commission onEuropean union horizonGain therapeutics incSwiss innovation agencyDuke school of medicine

Tranquis Therapeutics Announces Initiation of Phase 1 Study of TQS-168

Tranquis Therapeutics Announces Initiation of Phase 1 Study of TQS-168
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.

United kingdomSanjay kakkarEdgar englemanCory trombleeJonas hannestadFrederic godderisStanford universityTranquis therapeuticsChief medical officerProfessor edgar engleman

Vigil bags $90M to take ex-Amgen assets on path from rare diseases to Alzheimer s

Vigil Neuroscience is barreling forward with a strategy that will see it hop along steppingstones from rare diseases to Alzheimer’s. Having emerged with $50 million late last year, Vigil has gathered up an additional $90 million to validate its ex-Amgen asset in a rare, inherited neurodegenerative disease.

Arie belldegrun vidaVigil neuroscienceArie belldegrunVida venturesTranquis therapeuticsMuna therapeuticsவிழிப்புணர்வு நரம்பியல்விடா முயற்சிகள்முனா சிகிச்சைVida venturesNeurodegenerative diseasesAlzheimer 039 sAlzheimer 039s drugsRare diseasesVenture capital vc